Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to ...

Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its ...

VCs and universities struggle with different goals and timelines, but tech transfer is helping turn academic science into ...

Understanding these mechanisms potentially opens the way to the creation of smart medicines. However, experts point out that ...

BIO Asia–Taiwan 2026 Chairman Johnsee Lee highlighted three major features of this year's gathering. First, showcasing new ...

Financial terms include $40 million upfront for four programs, expansion options, and opt-out economics up to $535 million per program plus low double-digit royalties, totaling up to $2.1 billion.

Drug names are complicated things. For one, they must linguistically fulfill the role of being a shiny bauble for prescribers ...

If the FDA approves a drug for a neglected tropical disease, the company gets a voucher that accelerates review of another drug. This remains controversial.

GPT-Rosalind is OpenAI's first domain-specific model, built for drug discovery and life sciences—and it's not for everyone.

The cleanroom-compatible touch display, integrated into the stainless steel housing, shows a range of critical parameters ...

Kivo reports that quality control significantly drives up prescription costs by ensuring safety and compliance in the ...

Imagination pairs with plant breeding innovation using tools such as gene editing and cyber agriculture to redefine ...